Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amgen Inc. is conducting a long-term extension study titled ‘A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren’s Syndrome (SS)’. The study aims to assess the long-term safety and tolerability of the drug dazodalibep, which is significant for advancing treatment options for patients with Sjögren’s Syndrome.
The intervention being tested is dazodalibep, administered intravenously. It is designed to evaluate its safety and effectiveness in treating Sjögren’s Syndrome over an extended period.
The study follows an interventional design with a randomized allocation and a parallel intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment assignments, and its primary purpose is treatment.
The study began on February 25, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on August 20, 2025, indicating ongoing recruitment and progress.
This update could positively influence Amgen’s stock performance and investor sentiment, showcasing the company’s commitment to expanding its therapeutic portfolio. It also positions Amgen competitively within the pharmaceutical industry, particularly in the autoimmune disease segment.
The study is currently ongoing, with further details available on the ClinicalTrials portal.